Back to Journals » Biologics: Targets and Therapy » Volume 6

Review

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

       
Total article views   HTML views PDF downloads Totals
15,485 Dovepress* 11,605+ 2,538 14,143
PubMed Central* 3,880 1,190 5,070
Totals 15,485 3,728 19,213
*Since 25 September 2012
+Since July 2016

View citations on PubMed Central and Google Scholar